Landmark Research Studies
completed

POISE-3 was an international multicentre randomized clinical trial to assess the impact of tranexamic acid (TXA) versus placebo, and to assess the impact of managing hypotension versus standard of care (hypertension) in patients undergoing non-cardiac surgery who are at risk of a perioperative cardiovascular event.

The primary objective of POISE-3 was to determine the incidence of a composite of myocardial infarction, stroke and pulmonary embolism. Patients were followed for one year.

ACC22 - Tranexamic Acid - Download PDF ACC22 - Hypo/hypertension strategies - Download PDF POISE-3 Rationale - Download PDF
Study Type

Interventional - Drug

Study Design

Multi-centre, blinded, randomized controlled trial

NO. of Countries

24

NO. of Sites

149

NO. of Participants

9561

Study Period

2018 - 2022

Sponsor

PHRI

ACC 2022: PJ Devereaux discussed POISE-3 trial results

CIHR Foundation Grant

Back To Top